Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
The GLP-1 drug market has been dominated by pharmaceutical giant Novo Nordisk. Demand for these drugs have soared in ...
TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating ...